{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04748276",
            "orgStudyIdInfo": {
                "id": "TRAIT-MDD-107"
            },
            "organization": {
                "fullName": "Adams Clinical",
                "class": "NETWORK"
            },
            "briefTitle": "Tracking Response to Antidepressants in Advance of Investigational Trials",
            "officialTitle": "Tracking Response to Antidepressants in Advance of Investigational Trials",
            "acronym": "TRAIT",
            "therapeuticArea": [
                "Other"
            ],
            "study": "tracking-response-to-antidepressants-in-advance-of-investigational-trials"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2019-01-02",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2023-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2023-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-02-07",
            "studyFirstSubmitQcDate": "2021-02-07",
            "studyFirstPostDateStruct": {
                "date": "2021-02-10",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-03-23",
            "lastUpdatePostDateStruct": {
                "date": "2023-03-27",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Adams Clinical",
                "class": "NETWORK"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "TRAIT is an open-label observational study to evaluate treatment response to selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs) among individuals meeting criteria for Major Depressive Disorder (MDD) and seeking enrollment in investigational trials."
        },
        "conditionsModule": {
            "conditions": [
                "Major Depressive Disorder"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "CASE_ONLY",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 400,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)",
                    "description": "Protocol-approved antidepressant treatments (ADT) will be prescribed in accordance with standard of care, whenever possible following dosing recommendations within the Study Formulary and Prescribing Guidelines (Sertraline 100 mg/day; Citalopram 20 mg/day; Escitalopram 10 mg/day; Fluoxetine 20 mg/day; Paroxetine 20 mg/day; Duloxetine 60 mg/day; Buproprion 300 mg/day; Desvenlafaxine 50 mg/day; Venlafaxine 150 mg/day). ADTs may be up or down-tapered as necessary."
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in Hamilton Depression Inventory - 17 item (HAM-D) total score in response to a treatment cycle from Baseline/Day 0 to the end of a 6-week treatment cycle.",
                    "timeFrame": "Up to 33 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Failure to respond to 1, 2, or 3+ ADT treatment cycles, as defined as < 25% change in HAM-D total score from study Baseline/Day 0 to Day 42 of the participant's 1st, 2nd, or 3rd+ treatment cycles.",
                    "timeFrame": "Up to 33 weeks"
                },
                {
                    "measure": "Partial response to 1, 2, or 3+ ADT treatment cycles, as defined as \u2265 25% to < 50% change in HAM-D total score from study Baseline/Day 0 to Day 42 of the participant's 1st, 2nd, or 3rd+ treatment cycles.",
                    "timeFrame": "Up to 33 weeks"
                },
                {
                    "measure": "Total number of treatment cycles required to reach ADT response, as defined as \u2265 50% reduction in HAM-D score from Baseline/Day 0 to Day 42 of each treatment cycle.",
                    "timeFrame": "Up to 33 weeks"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Presence of and change in anxiety symptoms as assessed by the MDD with Anxious Distress subscale of the Mini-International Neuropsychiatric Inventory (MINI), and self-report on the Beck Anxiety Inventory (BAI).",
                    "timeFrame": "Up to 33 weeks"
                },
                {
                    "measure": "Presence of and change in sleep-related disturbance as assessed by the self-reported Insomnia Severity Index (ISI).",
                    "timeFrame": "Up to 33 weeks"
                },
                {
                    "measure": "Presence of and change in anger symptoms as assessed by the self-reported Massachusetts General Hospital Anger Attacks Questionnaire (MGH AAQ), and the self-reported Concise Associated Symptoms Tracking Scale (CAST-SR).",
                    "timeFrame": "Up to 33 weeks"
                },
                {
                    "measure": "Presence of and change in depression-/treatment- related sexual dysfunction as assessed by the self-reported Change in Sexual Functioning Questionnaire (CSFQ).",
                    "timeFrame": "Up to 33 weeks"
                },
                {
                    "measure": "Presence of and change in functional impairment as assessed by the Sheehan Disability Scale, Inventory of Depressive Symptomology, Short Form Survey Instruments, Patient Global Impressions, and the Clinical Global Impression scale.",
                    "timeFrame": "Up to 33 weeks"
                },
                {
                    "measure": "Presence of and change in pain conditions as assessed by the self-reported Brief Pain Inventory, Short Form (BPI-SF) and Visual Analog Scale - Pain (VAS-PAIN).",
                    "timeFrame": "Up to 33 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Participant has signed an ICF prior to any study-specific procedures being performed.\n* Participant is male or female of age \u2265 18 years old.\n* Participant has a diagnosis of MDD as confirmed by the MINI semi-structured diagnostic interview and \u2265 14 HAM-D total score.\n* Participant is in good physical health and, in the opinion of the investigator, is a suitable candidate for treatment with an ADT.\n\nExclusion Criteria:\n\n* Participant is pregnant, breast-feeding, or planning to become pregnant.\n* A history or presence of a clinically significant hepatic, renal, gastrointestinal, cardiovascular, endocrine, respiratory, immunologic, hematologic, dermatologic, or neurologic abnormality, which in the opinion of the investigator may impact participant safety or study results.\n* Participant has a history of any psychiatric condition other than MDD, which in the opinion of the investigator is primary, or any other psychiatric or neurologic disorder or symptom that could pose undue risk to the participant or compromise the study.\n* Any participant who represents an acute suicidal risk in the opinion of the investigator.\n* Moderate or severe substance use disorder within 90 days prior to screen, according to DSM-5 criteria that in the opinion of the investigator could pose undue risk to the participant, or compromise the study.\n* Any condition that, in the opinion of the investigator, makes the participant unsuitable for the study.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Adults who currently meet the Diagnostic and Statistical Manual - Version 5 (DSM-5) criteria for Major Depressive Disorder and are seeking enrollment in an industry-sponsored clinical trial of a second- or third-line antidepressant.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Stephanie Ellickson, PhD",
                    "role": "CONTACT",
                    "phone": "617-744-8542",
                    "email": "sellickson@adamsclinical.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Stephanie Ellickson, PhD",
                    "affiliation": "Adams Clinical",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Adams Clinical",
                    "status": "RECRUITING",
                    "city": "Watertown",
                    "state": "Massachusetts",
                    "zip": "02472",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Stephanie Ellickson, PhD",
                            "role": "CONTACT",
                            "phone": "617-744-8542",
                            "email": "sellickson@adamsclinical.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.37093,
                        "lon": -71.18283
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003866",
                    "term": "Depressive Disorder"
                },
                {
                    "id": "D000003865",
                    "term": "Depressive Disorder, Major"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019964",
                    "term": "Mood Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7058",
                    "name": "Depression",
                    "relevance": "LOW"
                },
                {
                    "id": "M7061",
                    "name": "Depressive Disorder",
                    "asFound": "Depressive Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7060",
                    "name": "Depressive Disorder, Major",
                    "asFound": "Major Depressive Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21835",
                    "name": "Mood Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009638",
                    "term": "Norepinephrine"
                },
                {
                    "id": "D000012701",
                    "term": "Serotonin"
                },
                {
                    "id": "D000017367",
                    "term": "Selective Serotonin Reuptake Inhibitors"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000316",
                    "term": "Adrenergic alpha-Agonists"
                },
                {
                    "id": "D000000322",
                    "term": "Adrenergic Agonists"
                },
                {
                    "id": "D000018663",
                    "term": "Adrenergic Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000013566",
                    "term": "Sympathomimetics"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000014662",
                    "term": "Vasoconstrictor Agents"
                },
                {
                    "id": "D000017366",
                    "term": "Serotonin Receptor Agonists"
                },
                {
                    "id": "D000018490",
                    "term": "Serotonin Agents"
                },
                {
                    "id": "D000014179",
                    "term": "Neurotransmitter Uptake Inhibitors"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12575",
                    "name": "Norepinephrine",
                    "asFound": "Adaptive",
                    "relevance": "HIGH"
                },
                {
                    "id": "M439",
                    "name": "Venlafaxine Hydrochloride",
                    "relevance": "LOW"
                },
                {
                    "id": "M8601",
                    "name": "Fluoxetine",
                    "relevance": "LOW"
                },
                {
                    "id": "M7104",
                    "name": "Dexetimide",
                    "relevance": "LOW"
                },
                {
                    "id": "M17983",
                    "name": "Citalopram",
                    "relevance": "LOW"
                },
                {
                    "id": "M2732",
                    "name": "Escitalopram",
                    "relevance": "LOW"
                },
                {
                    "id": "M15512",
                    "name": "Serotonin",
                    "asFound": "Incremental",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19649",
                    "name": "Selective Serotonin Reuptake Inhibitors",
                    "asFound": "Isometric exercises",
                    "relevance": "HIGH"
                },
                {
                    "id": "M299",
                    "name": "Duloxetine Hydrochloride",
                    "relevance": "LOW"
                },
                {
                    "id": "M22100",
                    "name": "Sertraline",
                    "relevance": "LOW"
                },
                {
                    "id": "M4247",
                    "name": "Antidepressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M19654",
                    "name": "Paroxetine",
                    "relevance": "LOW"
                },
                {
                    "id": "M437",
                    "name": "Desvenlafaxine Succinate",
                    "relevance": "LOW"
                },
                {
                    "id": "M20746",
                    "name": "Adrenergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M3668",
                    "name": "Adrenergic alpha-Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M3673",
                    "name": "Adrenergic Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M16345",
                    "name": "Sympathomimetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M17409",
                    "name": "Vasoconstrictor Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M19648",
                    "name": "Serotonin Receptor Agonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "VaCoAg",
                    "name": "Vasoconstrictor Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                },
                {
                    "abbrev": "AnDyAg",
                    "name": "Anti-Dyskinesia Agents"
                },
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                }
            ]
        }
    },
    "hasResults": false
}